首页> 外文期刊>Molecular biology reports >Development and verification of a three-dimensional (3D) breast cancer tumor model composed of circulating tumor cell (CTC) subsets
【24h】

Development and verification of a three-dimensional (3D) breast cancer tumor model composed of circulating tumor cell (CTC) subsets

机译:一种循环肿瘤细胞(CTC)子集组成的三维(3D)乳腺癌肿瘤模型的开发和验证

获取原文
获取原文并翻译 | 示例
           

摘要

Breast cancer is one of the most common cancer types among women in which early tumor invasion leads to metastases and death. EpCAM (epithelial cellular adhesion molecule) and HER2 (human epidermal growth factor receptor 2) are two main circulating tumor cell (CTC) subsets in HER2+ breast cancer patients. In this regard, the main aim of this study is to develop and characterize a three-dimensional (3D) breast cancer tumor model composed of CTC subsets to evaluate new therapeutic strategies and drugs. For this reason, EpCAM(+) and HER2(+) sub-populations were isolated from different cell lines to establish 3D tumor model that mimics in situ (in vivo) more closely than two-dimensional (2D) models. EpCAM(+)/HER2(+) cells had a high proliferation rate and low tendency to attach to the surface in comparison with parental MDA-MB-453 cells as CTC subsets. Aggressive breast cancer subpopulations cultured in 3D porous chitosan scaffold had enhanced cell-cell and cell-matrix interactions compared to 2D cultured cells and these 3D models showed more aggressive morphology and behavior, expressed higher levels of pluripotency marker genes, Nanog, Sox2 and Oct4. For the verification of the 3D model, the effects of doxorubicin which is a chemotherapeutic agent used in breast cancer treatment were examined and increased drug resistance was determined in 3D cultures. The 3D tumor model comprising EpCAM(+)/HER2(+) CTC subsets developed in this study has a promising potential to be used for investigation of an aggressive CTC microenvironment in vitro that mimics in vivo characteristics to test new drug candidates against CTCs.
机译:乳腺癌是早期肿瘤侵袭导致转移和死亡的女性中最常见的癌症类型之一。 EPCAM(上皮细胞粘附分子)和HER2(人表皮生长因子受体2)是HER2 +乳腺癌患者中的两个主要循环肿瘤细胞(CTC)子集。在这方面,本研究的主要目的是开发和表征由CTC子集组成的三维(3D)乳腺癌肿瘤模型,以评估新的治疗策略和药物。因此,从不同的细胞系中分离出EPCAM(+)和HER2(+)子群,以建立比二维(2D)模型更紧密地模拟的3D肿瘤模型,以更密切地逼近。与亲本MDA-MB-453细胞作为CTC子集相比,EPCAM(+)/ HER2(+)细胞具有高增殖率和较低的倾向于附着在表面上。与2D培养细胞相比,3D多孔壳聚糖支架培养的侵袭性乳腺癌群具有增强的细胞 - 细胞和细胞 - 基质相互作用,并且这些3D模型表达了更富有的形态和行为,表达了更高水平的多能性标志物基因,纳米,SOX2和OCT4。为了验证3D模型,研究了在3D癌症处理中使用的化学治疗剂的多柔比蛋白的影响,并在3D培养物中测定耐药性增加。本研究开发的包含EPCAM(+)/ HER2(+)CTC子集的3D肿瘤模型具有有希望的潜力,用于调查体内侵略性CTC微环境的侵袭性CTC微环境,以模仿体内特征以测试针对CTC的新药候选者。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号